Employing anti-PD-1/PD-L1 antibodies represents a potentially effective method to rejuvenate fatigued CD8+ T cells, thus amplifying the immune response toward tumors in patients with HCC (74). This evidence concerns the gene CD8A and hepatocellular carcinoma.